News for Xtant Medical Holdings, Inc. (XTNT)

Fourth Quarter Revenue: $31.5 million, a 12% increase from the same period in 2023.Full Year Revenue: $117.3 million, a 28% increase from 2023.Biologics Produc

Mar 06, 2025 / 09:30PM GMTOperator Good day, everyone, and welcome to the Xtant Medical fourth-quarter and year-end 2024 earnings. (Operator Intructions) It is

Full Year 2024 Revenue Growth of 28%Expects 2025 Revenue of $126 Million to $130 Million Without Need for Additional Capital BELGRADE, MT / ACCESS Newswire / Ma

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q4 2024 Results Conference Call March 6, 2025 4:30 PM ETCompany ParticipantsBrett Maas - Hayden IRSean Browne -...

Xtant Medical Holdings Inc (XTNT) is set to release its Q4 2024 earnings on March 6, 2025. The consensus estimate for Q4 2024 revenue is $31.80 million, and the

BELGRADE, MT / ACCESS Newswire / February 28, 2025 / Xtant Medical Holdings, Inc. (NYSE American:XTNT), a global medical technology company focused on surgical

Xtant Medical Holdings, Inc. (NYSE:XTNT) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsBrett Maas - IRSean Browne -...

Revenue: $27.9 million for Q3 2024, up 12% year-over-year, but fell short of the analyst estimate of $29.30 million.Net Loss: $5.0 million, or $(0.04) per shar

Xtant Medical Holdings Inc (XTNT) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $29.30 million, and the

Orthobiologics Market size was valued at USD 6.1 billion in 2022 and is poised to grow from USD 6.43 billion in 2023 to USD 9.87 billion by 2031...

Aug 09, 2024 / 01:00PM GMTOperator Welcome to the Xtant Medical Holdings, Inc. second-quarter 2024 conference call. (Operator Instructions) I would now like to

Wilmington, Delaware, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, 'Demineralized Allografts Market by Application (Spinal fusion, Craniomaxillofacial surgery, Joint reconstruction and Others), and End user (Hospitals, Specialty clinics and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033'. According to the report, the demineralized allografts market was valued at $0.7 billion in 2023, and is estimated to reach $1.1 billion by 2033, growing at a CAGR of 4.6% from 2024 to 2033.

Wilmington, Delaware, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled,

Advancements and Projections in the Global Degenerative Disc Disease Treatment Market: Insights, Trends, Opportunities, and Recent Developments...

BioStem has enjoyed exceptional growth in its first year as a public company, with revenues soaring. Read why I think BSEM stock is a strong buy.

Xtant Medical Holdings, Inc. (NYSE:NYSE:XTNT) Q2 2024 Earnings Conference Call August 9, 2024 9:00 AM ETCompany ParticipantsBrett Maas - IRSean Browne -...

Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont., April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings,...

In this article, we will take a look at the 13 high growth penny stocks that are profitable.

Xtant Medical Holdings Inc (XTNT) announced a record third-quarter revenue of $25 million, marking a 73% increase year-over-year.The company reported a signifi